Be quiet and you'll keep young: does mTOR underlie p53 action in protecting against senescence by favoring quiescence?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. HIV infection in microglia leads to senescence, triggering activation of neurotoxicity pathways.bioRxiv : the preprint server for biology · 2025
   Article
2. Is cellular senescence involved in cystic fibrosis?Respiratory research · 2019
   Review
3. The cell fate: senescence or quiescence.Molecular biology reports · 2016
   Review
4. cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response.Cell cycle (Georgetown, Tex.) · 2016
   Article
5. Long-term quiescent fibroblast cells transit into senescence.PloS one · 2014
   Article
6. TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.Cell death & disease · 2013
   Review
7. Immunosuppressants in cancer prevention and therapy.Oncoimmunology · 2013
   Review
8. Selective anti-cancer agents as anti-aging drugs.Cancer biology & therapy · 2013
   Article
9. Dysregulation of the mTOR pathway in p53-deficient mice.Cancer biology & therapy · 2013
   Article
10. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.Cell cycle (Georgetown, Tex.) · 2013
    Article
11. M(o)TOR of aging: MTOR as a universal molecular hypothalamus.Aging · 2013
    Article
12. p63 the guardian of human reproduction.Cell cycle (Georgetown, Tex.) · 2012
    Review
13. Advances in targeting signal transduction pathways.Oncotarget · 2012
    Review
14. Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging.Aging · 2012
    Article
15. Answering the ultimate question "what is the proximal cause of aging?".Aging · 2012
    Review
16. Tissue-specific expression of p73 C-terminal isoforms in mice.Cell cycle (Georgetown, Tex.) · 2012
    Article
17. Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.Cell cycle (Georgetown, Tex.) · 2012
    Article
18. Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.Oncotarget · 2012
    Review
19. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Oncotarget · 2012
    Review

Corrections and comments

• Comment on
  DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.2010

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as